Q-omics provides the consensus-scored CLEC19A profile across patient tissues and cancer cell-line models. CLEC19A expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLEC19A is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, CLEC19A RNA expression shows 9,778 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where CLEC19A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC19A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC19A survival associations across molecular data types. CLEC19A RNA expression shows survival associations in the most cancer types (15), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC19A RNA expression–survival associations across cancer types. High CLEC19A expression shows unfavorable associations in KIRC, LUSC, SKCM, COAD and LGG, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLEC19A RNA expression.
This table summarizes CLEC19A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CLEC19A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC19A shows lower tumor expression in LUSC, COAD and LUAD and higher tumor expression in STAD, BRCA and KICH. The LUSC box plot shows higher CLEC19A RNA expression in normal versus tumor tissue (log2 FC = −0.438, t-test p < 0.001).
This table shows molecular features associated with CLEC19A in patient tissues and cancer cell lines. In patient samples, CLEC19A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC19A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BREAST.
